Trial Status
Open for enrollment

What is the Purpose of this Study?
To study the effects of IMO-8400 on Dermatomyositis (DM).

Who is Eligible to Participate?
Patients ages 18 to 75 with a diagnosis of DM, with a CDASI score greater than 15. Patients will also have to meet all inclusion criteria, which will be explained in greater detail by the study coordinator.

What is involved in this Study?
Patients will be given Sub-Q injections of IMO-8400 or placebo once a week for 24 weeks. Patients will complete 24 in-person follow up appointments

How long is the Study?
This study will be approximately 2 years long.

For more information contact:
Lynette McKinney, MSCS, CRC, Study Coordinator at 602-358-2271 or lmckinney@pnal.net